An interventional study of Vascular flow measurement by PC-MRI in Alzheimer Disease, sponsored by Central Hospital Saint Quentin. Status unknown at 1 site in France. Open to participants aged 75 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-14.
Sponsored by Central Hospital Saint Quentin · Not applicable, Interventional, and Diagnostic
Among 438 studies in Alzheimer Disease with a site in France — 80 open to participants now, 97 under way, 19 of them phase 3. Alzheimer Disease · France.
Among the 438 studies in Alzheimer Disease with a site in France, this one is the 178th largest by planned enrollment of the 342 interventional ones that give a count, is one of 20 that started in 2015, is one of 168 with no phase, and was the 196th registered.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
Browse Alzheimer Disease studies →80 of the 438 studies in Alzheimer Disease with a site in France are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in France, United States, Australia
Firalis SA · Sites in France
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
University Hospital, Toulouse · Sites in France
Central Hospital, Nancy, France · Sites in France
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 641 Alzheimer Disease studies recruiting now, 283 (44%) set no upper age limit and 54 (8%) stop at 75 or younger; 34 take children under 18; 283 take healthy volunteers.
This study: 75 Years to 120 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
438 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 72 · Phase 3 88 · Phase 4 7
First in 2001; this study’s year is marked. 20 started in 2015.
This study's planned enrollment of 139 is above the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.
Median enrollment 154 across the 342 interventional studies, 140 across the 93 observational. Of the 290 that completed or were terminated, 74 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
156 of 438 have an industry lead sponsor. The 10 most frequent:
Central Hospital Saint Quentin is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
Central Hospital Saint Quentin has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
32 of the studies in Alzheimer Disease with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06080659Rennes University HospitalNetwork-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity | 2026-11 |
| NCT06402838Hoffmann-La RocheA Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | 2026-11-19 |
Among the 438 studies in Alzheimer Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obstructive sleep apnea syndrome (OSAS) is a sleep-disordered breathing characterized by the occurrence of repeated upper airway obstructions leading to airflow reduction (hypopnea) or cessation (apnea). The apnea-hypopnea index (AHI) is the number of apneas and hypopneas per hour of sleep. OSA patients often report cognitive complaints.
About 25% of the elderly population is affected by this syndrome with a drastic increase of this rate among dementia patients. OSAS is considered to be an important risk factor for the development of hypertension, heart disease and stroke.
Numerous studies pointed out the close relationship between sleep apnea and cognitive impairment. To the investigators' knowledge, no trials have assessed the existence of a relationship between the IAH index and the cerebral arterial blood flow rate (macrocirculation). Developments in magnetic resonance imaging (MRI) provide new insights into the quantitative study of blood flow through phase contrast MRI also called "flow MRI". The main hypothesis tested in this study is the existence of a relationship between OSAS and total cerebral arterial vascular inflow measured by PC-MRI (in mL/min) in the elderly population.
Secondary outcomes:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Dementia Group:
3.1. (Mini Mental State Examination)> 15
3.2. Diagnosis of dementia established according to
3.3. Dementia of the Alzheimer type from NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association)
Control Group:
Preserved cognitive function corresponding to a normal MMSE score by the standards of Poitrenaud
Exclusion Criteria:
Anyone with a classic to MRI
2.1 Major behavioral disorders that do not allow the realization of MRI in optimal conditions
2.2 Claustrophobia
2.3 Presence of foreign non-compliant material
2.4 Presence of intraocular metal body
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia). ROC method will be used to find a threshold value of IAH that separates the two groups. Interventions: * Vascular flow measurement by PC-MRI * Neuropsychological assessment * Registration of sleep apnea * Registration of blood pressure * ECG holters * Blood test * Geriatric standard evaluation
Other: Vascular flow measurement by PC-MRI
Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia). ROC method will be used to find a threshold value of IAH that separates the two groups. Interventions: * Vascular flow measurement by PC-MRI * Neuropsychological assessment * Registration of sleep apnea * Registration of blood pressure * ECG holters * Blood test * Geriatric standard evaluation
Other: Vascular flow measurement by PC-MRI
participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels
Total arterial flowrate (measured by PC-MRI debit ml/Mn)
Time frame: at day 1 after inclusion
sleep apnea measured by elderly polygraphy (Number of apneas / night)
Time frame: at day 1 after inclusion up to 24 heures
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of May 2015, a primary completion of Jan 2022 and a completion of Jan 2022. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Central Hospital Saint Quentin